Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
2(40.0%)
5Total
Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07318155Phase 2Recruiting

A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease

Role: lead

NCT07557355Phase 1Not Yet Recruiting

A Study of SRSD384 in Overweight or Obese Participants

Role: lead

NCT07140523Phase 2Recruiting

A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA

Role: lead

NCT07172646Phase 1Recruiting

A Study of SRSD216 in Patients With Elevated Lipoprotein (a)

Role: lead

NCT06116617Phase 1Completed

A Phase 1 Study to Evaluate the Safety, Tolerability, PK/PD of SRSD107 in Healthy Participants

Role: lead

All 5 trials loaded